Next generation sequencing targeting NOTCH1/2/3 genes and/or NOTCH1 intra-cellular domain (NICD1) has indicated that patients with NOTCH pathway activated AdCC have worse clinical outcomes [152,153]. The gene discussed is NOTCH1; the disease is adrenocortical carcinoma, hereditary.